EY’s annual assessments of medtech deal-making by market segment and disease area indicate deal volume in therapeutic devices has remained steady over the past several years, with roughly 50 percent of all mergers occurring in this space since July 2009.
According to the report, therapeutic devices’ share of the total mergers and acquisitions dollars experienced a spike during the 12-month time period because of Medtronic’s purchase of Covidien and Zimmer’s purchase of Biomet. Therapeutic devices comprised 92 percent of total deal value in June 2014, up from 63 percent in June 2013.
The following list includes the percent of the total deal value of medtech mergers and acquisitions by market segment and disease area between July 2013 and June 2014, according to the report.
- Therapeutic devices — 92 percent of total M&A deal value
-
- Multiple — 61 percent
- Orthopedic — 21 percent
- Cardiovascular — 3 percent
- Ophthalmic — 2 percent
- Non-disease specific — 1 percent
- Wound care — 1 percent
- All others — 1 percent
- Research and other equipment — 2 percent
- Non-imaging diagnostics — 2 percent
- Imaging — 1 percent
- Other — 3 percent
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
